AZ diabetes combo passes Phase III test

AstraZeneca plc (LSE:AZN; NYSE:AZN) said a combination of Bydureon exenatide plus Farxiga dapagliflozin met the primary endpoint in the Phase III DURATION-8 study to treat Type II diabetes. Patients receiving the combination achieved greater reductions in HbA1c than either component alone after 28 weeks (2% combo vs. 1.6% Bydureon and 1.4% Farxiga; p<0.01 for both).

The combo also led to significantly greater weight loss (p<0.01 for both) and lower systolic blood pressure (p<0.05 for both) over either monotherapy, meeting secondary endpoints. ...